title: Effects of anti-IgM on mitogen-induced proliferation of human B-lymphocyte malignancies.
abstract: Therapeutic trials of anti-immunoglobulin antibody have produced a wide range of responses in attempts to control the growth of human B lymphoid neoplasms. This variability might reflect differences in intrinsic functional characteristics of malignant B lymphocytes that determine susceptibility to anti-immunoglobulin-mediated regulation of growth. To characterize B-lymphocyte malignancies, tissue samples from 24 patients were studied during short-term culture in vitro. Malignant B lymphocytes were stimulated to proliferate by the T-independent mitogens lipopolysaccharide, cytochalasin B, and Staphylococcus aureus that bears protein A. The effects of monoclonal mouse anti-human IgM on mitogen-induced malignant lymphocyte proliferation were then assessed. Mitogen-induced responses of malignant lymphocytes from three patients were abrogated by 2 micrograms/ml monoclonal anti-human IgM. Proliferation was also abrogated by polyclonal goat anti-IgM antiserum but proliferative responses were not affected by control monoclonal antibody. Further study showed that anti-immunoglobulin-mediated inhibition of proliferation was not dependent on Fc-determined interactions, nor was it dependent on the presence of T lymphocytes. These results indicate that a subset of human B-lymphocyte malignancies are susceptible to inhibition of proliferation mediated by anti-IgM.
authors.forename: T R
authors.initials: TR
authors.lastname: Baeker
authors.forename: T L
authors.initials: TL
authors.lastname: Rothstein
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D000955:Antigens, T-Independent / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology*; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000276:immunology; D007075:Immunoglobulin M / Q000276:immunology*; D007167:Immunotherapy; D007943:Leukemia, Hairy Cell / Q000628:therapy*; D007945:Leukemia, Lymphoid / Q000628:therapy*; D008213:Lymphocyte Activation; D008223:Lymphoma / Q000628:therapy*; D008934:Mitogens / Q000276:immunology; D011947:Receptors, Antigen, B-Cell / Q000276:immunology; D008258:Waldenstrom Macroglobulinemia / Q000628:therapy*
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D000955:Antigens, T-Independent; D007141:Immunoglobulin Fc Fragments; D007075:Immunoglobulin M; D008934:Mitogens; D011947:Receptors, Antigen, B-Cell